Nuclear factor kappa B (NF-jB) signaling pathway is activated in many colorectal cancer (CRC) cells and in the tumor microenvironment, which plays a critical role in cancer initiation, development, and response to therapies. In the present study, we found that the widely used antimalarial drug mefloquine was a NF-jB inhibitor that blocked the activation of IjBa kinase, leading to reduction of IjBa degradation, decrease of p65 phosphorylation, and suppressed expression of NF-jB target genes in CRC cells. We also found that mefloquine induced growth arrest and apoptosis of CRC cells harboring phosphorylated p65 in culture and in mice. Furthermore, expression of constitutive active IKKb kinase significantly attenuated the cytotoxic effect of the compound. These results showed that mefloquine could exert antitumor action through inhibiting the NF-jB signaling pathway, and indicated that the antimalarial drug might be repurposed for anti-CRC therapy in the clinic as a single agent or in combination with other anticancer drugs.
p65/p50 complex is the most common active heterodimer. 9, 10 They normally stay inactive as a result of binding with IjB in the cytoplasm. Inflammatory and immunological stimuli are able to activate IjB kinase (IKK), which, in turn, phosphorylates IjBa and promotes its ubiquitination and proteasomal degradation, resulting in nuclear translocation of NF-jB. Once in the nucleus, p65 often undergoes a series of post-translational modifications including phosphorylation, acetylation, and methylation, which regulate both the strength and duration of the transactivation activity. The target genes of NF-jB include cell survive-related Bcl-2 and XIAP, cell proliferation-related Cyclin D1, CDK2 and MYC, and pro-inflammatory cytokines. Not unexpectedly, the NF-jB pathway is aberrantly activated in many tumors and is closely associated with their development and progress. In CRC, NF-jB is activated in cancer cells as well as in the surrounding microenvironment to sustain inflammation and promote proliferation, angiogenesis, invasion and eventually metastasis. Retrospective analysis indicated that activated NF-jB is associated with tumor metastasis and poor prognosis. 11, 12 Thus, targeting the NF-jB pathway has been an actively sought-after strategy for novel anti-CRC drug discovery, and a number of specific inhibitors have been developed for further clinical studies. 13 Through screening a library of FDA-approved drugs with a NF-jB response element-driven luciferase reporter, we found that one of the effective inhibitors of NF-jB-dependent transcription is mefloquine, an effective drug used to prevent and treat malaria. 14 Our studies
showed that mefloquine suppressed NF-jB activity by inhibiting IKK activation, and induced apoptosis in CRC cells both in vitro and in vivo, which could be attenuated by expressing constitutively active IKK in the cells. These results indicated that mefloquine could potentially be repurposed as a chemotherapeutic for the treatment of CRC.
| MATERIALS AND METHODS

| Cells, culture and chemicals
Colorectal cancer cell lines HT-29, HCT116, RKO, SW620 and Lovo were purchased from ATCC (Manassas, VA, USA). HEK293T cell line was kindly provided by Dr Huashun Li from Tongji University, Shanghai, China. All CRC cell lines and HEK293T were maintained in DMEM supplemented with 10% FBS, 100 lg/mL penicillin, and 100 units/mL streptomycin. The 104-compound library and IKK-16
were purchased from Selleck Chemicals (Houston, TX, USA). Doxorubicin (DOX), mefloquine (Mef), and tumor necrosis factor alpha (TNF-a) were purchased from Sigma-Aldrich (St Louis, MO, USA).
| Plasmid construction and gene transfection
Human constitutively activated IKKb (CA-IKKb) gene was generated and cloned into pcDNA3.1 vector with a Flag tag as previously described. 15 A NF-jB luciferase construct (pNF-jB-Luc) driven by specific NF-jB response elements was purchased from Beyotime Biotechnology Institute (Nantong, China). siRNAs against IKKb (siIKKb) and the negative control (siNC) were purchased from Guangzhou Ribobio Co., Ltd (Guangzhou, China). 
| Immunofluorescence staining
HCT116 cells were cultured on sterile glass coverslips in 6-well plates to 80% confluence in DMEM. HCT116 cells were then starved overnight, followed by incubation with mefloquine or DMSO for 2 hours.
Cells were then treated with 50 ng/mL TNF-a or DMSO for 20 minutes. Finally, the cells were subjected to confocal microscopic analysis.
For confocal microscopic analysis, cells were fixed in 4% paraformaldehyde at room temperature for 10 minutes and permeabilized in 0.5%
Triton-100 for 5 minutes. Cells were then blocked in TBS containing 3% BSA for 1 hour at room temperature before being stained with anti-p-p65 overnight at 4°C. Cells were then gently washed and incubated with FITC-conjugated goat anti-rabbit IgG (Beyotime Biotechnology Ltd). After 3 brief washes with PBS, slides were stained with 5 lg/mL DAPI for 10 minutes. After 3 more washes with PBS, the slides were mounted with Slowfade gold anti-fade reagent (Invitrogen).
Protein expression was visualized on Leica confocal microscopy.
| Statistical analysis
Student's t test was used for comparisons of the 2 groups. All statistical tests were 2-sided and P-value < .05 was considered statistically significant. Luciferase activity was measured followed by stimulation with tumor necrosis factor alpha (TNF-a) or control vehicle for 20 min. *P < .05, **P < .01
3 | RESULTS
| Mefloquine inhibits NF-jB in colorectal cancer cells
To find novel inhibitors for the NF-jB signaling pathway, a luciferase reporter system driven by the NF-jB response elements was used to screen a library of 104 FDA-approved anti-infectious drugs.
As shown in Figure 1A and Table S1 , a number of compounds from the library decreased luciferase activity significantly in HEK293T cells transfected with the reporter. Among them, the antimalarial drug mefloquine reduced luciferase activity more than 2-fold and also decreased cell viability, so was selected for further assessment (Figure 1A ,B; Figure S1 ). As shown in Figure 1C , mefloquine inhibited both spontaneous and TNF-a-induced NF-jB-driven luciferase activities dose-dependently, and was therefore an effective NF-jB inhibitor.
We then examined the effects of mefloquine on the growth After treatment with mefloquine, phosphorylated p65 in HCT116
and RKO cells was decreased dose-dependently ( Figure 2C ). Noteworthily, TNF-a increased phosphorylated p65 in these cells, which was also abolished by pretreatment with mefloquine (Figure 2D ; Figure S2 ). Furthermore, the expression of NF-jB target genes Cyclin D1, Bcl-2 and XIAP was assessed by RT-qPCR. As shown in Figure 2E , their levels were downregulated significantly by mefloquine. These results indicated that mefloquine is a NF-jB inhibitor in CRC cells.
| Mefloquine inhibits IKK activation
To understand the mechanisms of inhibiting p65 phosphorylation and NF-jB transactivation by mefloquine, we examined the statuses of upstream regulatory molecules IjBa, IKKa and IKKb in RKO and HCT116 cells. 21 As shown in Figure 3A , exposure to mefloquine for 15 minutes resulted in a significant decrease of phosphorylated IjBa, which is required for its ubiquitination and proteasomal degrada- To further assess the role of IKK inhibition, a constitutively activated IKKb (CA-IKKb) was generated and transfected into HCT116 cells. 15 As shown in Figure 3D , transfection of CA-IKKb led to increase of phosphorylated IjBa and decrease of total IjBa. Moreover, mefloquine-induced decrease of p-IjBa and p-p65 was markedly reversed in CA-IKKb-expressing cells ( Figure 3E ). These results indicated that blocking IKK activation is critical for the inhibitory action of mefloquine on NF-jB signaling.
| Mefloquine induces apoptosis in CRC cells
The inhibitory action of mefloquine on IKK and NF-jB activation prompted us to further examine its effects on the growth and survival of CRC cells. As shown in Figure 4A Immunoblotting also showed that the apoptosis-inhibiting proteins Bcl-2, MCl-1, and XIAP were all downregulated, whereas the proapoptotic BH3-only protein Bim was elevated in mefloquine-treated cells ( Figure 4C ). These data showed that mefloquine induced apoptosis of these CRC cells. Furthermore, when HCT116 cells were transfected with CA-IKKb, mefloquine-induced cell death was significantly attenuated, suggesting the involvement of IKK inhibition in the process (Figure 4D,E) . ) were inoculated s.c. into nude mice. When the tumors became palpable, mice were randomly divided into 2 groups (n = 6/group). One group was orally given mefloquine (30 mg/kg bodyweight) in PBS containing 10% Tween 80 and 10% DMSO daily for a continuous 20 days. Another group was given vehicle as a control. Tumor volumes were monitored every other day. *P < .05; **P < .01; ***P < .001. B, Tumors were excised at the end of the experiment and (C) their weights were measured. D, Tumor tissues were analyzed by immunoblotting of p-p65 and p65. GAPDH was used as an internal control clinically. 23 The finding that downregulation of NF-jB sensitized cancer cells to anti-cancer drugs led us to examine whether mefloquine affected the effect of doxorubicin on CRC cells. [24] [25] [26] As shown in Figure 6A , doxorubicin or mefloquine alone led to~25% and~50% reduction of viability, respectively, in both HCT116 and RKO cells as measured by CCK-8 assay. When the cells were treated with both drugs simultaneously, the viability reduction increased to~80%.
Mefloquine and doxorubicin also acted synergistically to inhibit p65 phosphorylation and to induce PARP cleavage ( Figure 6B) , showing that mefloquine significantly enhanced the cytotoxic action of doxorubicin.
Use was also made of the genetic approach to explore the synergistic action. Two siRNAs were selected to knock down IKKb in HCT116 cells ( Figure 6C ). Although cell viability assessed by CCK-8 decreased to only~80% when HCT116 cells were treated with doxorubicin alone overnight, it decreased markedly to~40% with IKKb knockdown in the system. Therefore, blocking the NF-jB pathway enhances the cytotoxic activity of doxorubicin, which likely accounts for the synergistic action of mefloquine.
| DISCUSSION
Colorectal cancer presents a specific challenge in the clinic because of its high incidence rate and demands long period of chemotherapy.
It is not uncommon to have CRC patients with metastasized tumor and rising serum levels of carcinoembryonic antigen (CEA) seeking treatment. Thus, novel, effective and low toxicity drugs are urgently needed to treat CRC. It has been indicated that repurposing existing drugs will enable us to cut down the time and financial limitations of advancing an anti-cancer program from hits and leads to clinical candidates. In fact, successful lists are growing impressively, 27 including the discovery that the anti-diabetic drug metformin has significant anti-neoplastic action. 28 We started with screening for compounds that inhibit NF-jB-mediated transactivation and found that the antimalarial drug mefloquine blocked NF-jB activation and induced apoptosis in colorectal cells harboring constitutively activated p65. Thus, it is conceivable that the drug widely used for malaria prevention and treatment might be tried for CRC that are addicted to activated NF-jB. Interestingly, it has been found that mefloquine induced breast cancer cell death by inhibiting autophagy, killed prostate cancer cells by reactive oxygen species (ROS)-mediated mechanisms, and inhibited the proliferation of gastric cancer cells through blocking the PI3K/Akt/mTOR signaling pathway. [29] [30] [31] Therefore, mefloquine appears to be an effective agent for many types of cancers, although it remains to be determined whether there is a common mechanism responsible for its action in different cancer cells. It was also shown that mefloquine may target the 80S ribosome of Plasmodium falciparum to inhibit protein synthesis. 32 Whether similar action of mefloquine takes place in mammalian cells and contributes to its anti-CRC action remains to be further investigated. Noteworthily, a number of anti-cancer and anti-inflammation agents have been found as effective anti-parasite chemicals, 33 whereas anti-leishmanial thiadiazine derivatives and anti-plasmodium are potent anti-neoplastic agents, [34] [35] [36] suggesting that we should cross-examine more therapeutic agents in both parasites and cancer systems.
NF-jB is activated in many different cancers, and has been reported to be overexpressed in 50%-75% of CRC. 37 Its activation is also related to resistance to chemotherapeutics and poor prognosis of patients with CRC. 38 Hence, the NF-jB pathway is widely 
